Leukopoiesis is not affected after intravenous treatment with the novel antineoplastic agent taurolidine: Results of an experimental study in rats

European Surgical Research

Volumn 40, Issue 4, 2008, Pages 341-346

  Braumann, C ^a   Menenakos, C ^a   Atanassov, V ^a   Pfirrmann, R W ^a   Guenther, N ^a   Jacobi, C A ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Intravenous treatment; Leukopoiesis; Taurolidine, rats

Indexed keywords

SODIUM; TAUROLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CONTROLLED STUDY; GRANULOCYTE; HUMAN; HUMAN CELL; LEUKOCYTE; LEUKOPOIESIS; MALE; MONOCYTE; MULTIPLE CYCLE TREATMENT; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; TREATMENT DURATION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; LEUKOPOIESIS; MALE; RANDOM ALLOCATION; RATS; TAURINE; THIADIAZINES;

EID: 43949084754     PISSN: 0014312X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000118030     Document Type: Article

References (20)

1. Calabresi P, Goulette FA, Darnowski JW: Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent. Cancer Res 2001;61:6816-6821.
2. Pfirrmann RW: Einführung und Übersicht. Taurolin - Ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infektionen. Munich, Urban &Schwarzenberg, 1985, pp 3-23.
3. Stendel R, Scheurer L, Schlatterer K, Gminski R, Mohler H: Taurolidine-Fibrin-Sealant-Matrix using spray application for local treatment of brain tumors. Anticancer Res 2004;24:631-638.
4. Petrovic L, Schlegel KA, Ries J, et al: In vitro effect of taurolidine on squamous cell carcinoma in the oral cavity. Mund Kiefer Gesichtschir 2003;7:102-107.
5. Jacobi CA, Peter FJ, Wenger FA, Ordemann J, Muller JM: New therapeutic strategies to avoid intra- and extraperitoneal metastases during laparoscopy: results of a tumor model in the rat. Dig Surg 1999;16:393-399.
6. Braumann C, Stuhldreier B, Bobrich E, Menenakos C, Rogalla S, Jacobi CA: High doses of taurolidine inhibit advanced intraperitoneal tumor growth in rats. J Surg Res 2005;129:129-135.
7. Braumann C, Ordemann J, Kilian M, Wenger FA, Jacobi CA: Local and systemic chemotherapy with taurolidine and taurolidine/ heparin in colon cancer-bearing rats undergoing laparotomy. Clin Exp Metastasis 2003;20:387-394.
8. Ismail M, Henklein P, Huang X, Braumann C, Ruckert RI, Dubiel W: Identification of HIV-1 Tat peptides for future therapeutic angiogenesis. Eur J Haematol 2006;77:157-165.
9. Mackenzie MJ, Saltman D, Hirte H, et al: A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma: a trial of the Princess Margaret Hospital Phase II consortium. Invest New Drugs 2007;25:553-558.
10. Riedel RF, Andrews C, Garst J, et al: A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. J Thorac Oncol 2007;2:520-525.
11. Artym J, Zimecki M, Kruzel M: Normalization of peripheral blood cell composition by lactoferrin in cyclophosphamide-treated mice. Med Sci Monit 2004;10:BR84-BR89.
12. Freyer G, Ligneau B, Trillet-Lenoir V: Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia. Int J Antimicrob Agents 1998;10:3-9.
13. O'Brien GC, Cahill RA, Bouchier-Hayes DJ, Redmond HP: Co-immunotherapy with interleukin-2 and taurolidine for progressive metastatic melanoma. Ir J Med Sci 2006;175:10-14.
14. Nestler G, Schulz HU, Schubert D, Kruger S, Lippert H, Pross M: Impact of taurolidine on the growth of CC531 coloncarcinoma cells in vitro and in a laparoscopic animal model in rats. Surg Endosc 2005;19:280-284.
15. Braumann C, Ordemann J, Wildbrett P, Jacobi CA: Influence of intraperitoneal and systemic application of taurolidine and taurolidine/ heparin during laparoscopy on intraperitoneal and subcutaneous tumour growth in rats. Clin Exp Metastasis 2000;18:547-552.
16. Walters DK, Muff R, Langsam B, Gruber P, Born W, Fuchs B: Taurolidine: a novel antineoplastic agent induces apoptosis of osteosarcoma cell lines. Invest New Drugs 2007;25:305-312.
17. Bedrosian I, Sofia RD, Wolff SM, Dinarello CA: Taurolidine, an analogue of the amino acid taurine, suppresses interleukin 1 and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokine 1991;3:568-575.
18. Yanagisawa M, Imai H, Fukushima Y, Yasuda T, Miura AB, Nakamoto Y: Effects of tumour necrosis factor alpha and interleukin 1 beta on the proliferation of cultured glomerular epithelial cells. Virchows Arch 1994;424:581-586.
19. Da Costa ML, Redmond HP, Bouchier-Hayes DJ: Taurolidine improves survival by abrogating the accelerated development and proliferation of solid tumors and development of organ metastases from circulating tumor cells released following surgery. J Surg Res 2001;101:111-119.
20. Braumann C, Winkler G, Rogalla P, Menenakos C, Jacobi CA: Prevention of disease progression in a patient with a gastric cancer re-recurrence: outcome after intravenous treatment with the novel antineoplastic agent taurolidine - report of a case. World J Surg Oncol 2006;4:34.